P0179 Severe hypersensitivity reactions with original and generic taxanes: A prospective study at a medical oncology unit in Thailand

2014 ◽  
Vol 50 ◽  
pp. e61
Author(s):  
T. Ratanajarusiri ◽  
V. Sriuranpong ◽  
S. Tanasanvimon
Keyword(s):  
Prospective Study ◽  
Medical Oncology ◽  
Hypersensitivity Reactions ◽  
Oncology Unit ◽  
A Prospective Study

A prospective study of costs associated to the evaluation of non‐steroidal anti‐inflammatory hypersensitivity reactions

Allergy ◽  
2020 ◽  
Vol 75 (6) ◽  
pp. 1495-1497 ◽  
Author(s):  
Miriam Sobrino‐García ◽  
Francisco J. Muñoz‐Bellido ◽  
Esther Moreno ◽  
Eva Macías ◽  
María‐Teresa Gracia‐Bara ◽  
...  
Keyword(s):  
Prospective Study ◽  
Hypersensitivity Reactions ◽  
Anti Inflammatory ◽  
A Prospective Study

A Difference in the Incidences of Hypersensitivity Reactions to Original and Generic Taxanes

Chemotherapy ◽  
2016 ◽  
Vol 62 (2) ◽  
pp. 134-139 ◽  
Author(s):  
Tanchanok Ratanajarusiri ◽  
Virote Sriuranpong ◽  
Piyada Sitthideatphaiboon ◽  
Nattaya Poovoravan ◽  
Chanida Vinayanuwat ◽  
...  
Keyword(s):  
Hypersensitivity Reaction ◽  
Prospective Study ◽  
Active Surveillance ◽  
Generic Drugs ◽  
Hypersensitivity Reactions ◽  
Paclitaxel Group ◽  
Life Threatening ◽  
Grade 3 ◽  
A Prospective Study ◽  
Docetaxel Group

Purpose: To compare incidences of hypersensitivity reaction (HSR) between original and generic taxanes including paclitaxel and docetaxel. Methods: We conducted a prospective study enrolling all patients receiving taxanes at King Chulalongkorn Memorial Hospital. Taxanes were infused accordingly to the step-wise rate escalation protocol at this hospital. Active surveillance for HSRs was performed. During the study period, there was only 1 generic brand used for each taxane. We primarily compared the incidences of HSR between original and generic drugs for each taxane. Results: During the period from January 1 to December 31, 2013, a total of 258 consecutive patients receiving taxanes were enrolled; 128 received paclitaxel, i.e. 65 and 63 in the original (Taxol) and generic arms, respectively, and 130 received docetaxel, i.e. 66 and 64 in the original (Taxotere) and generic arms, respectively. Premedication, including antihistamines and dexamethasone, was administered to all patients 30 min before taxane infusion. There were 26 (10.0%) HSR events including 24 grade 2 and 2 grade 3 HSRs. In the paclitaxel group, there were 9 (13.8%) and 7 (11.1%) HSRs in the original and generic arms, respectively (p = 0.791). In the docetaxel group, there were 9 (13.6%) and 1 (1.6%) HSRs in the original and generic arms, respectively (p = 0.017). No life-threatening symptoms or permanent discontinuation of taxanes occurred. Conclusions: In this prospective study, the incidences of HSR were similar with generic and original paclitaxel but significantly different with generic and original docetaxel.

The Frequency and Clinical Features of Hypersensitivity Reactions to Antiepileptic Drugs in Children: A Prospective Study

2018 ◽  
Vol 6 (6) ◽  
pp. 2043-2050 ◽  
Author(s):  
Hakan Guvenir ◽  
Emine Dibek Misirlioglu ◽  
Ersoy Civelek ◽  
Muge Toyran ◽  
Betul Buyuktiryaki ◽  
...  
Keyword(s):  
Prospective Study ◽  
Antiepileptic Drugs ◽  
Clinical Features ◽  
Hypersensitivity Reactions ◽  
A Prospective Study

A prospective study to assess the effect of a discharge intervention on readmission rates in patients with a low Rothman Index score admitted to the inpatient oncology unit.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e18198-e18198
Author(s):  
Tara Beth Sanft ◽  
Olatokunbo Famakinwa ◽  
Salimah Velji ◽  
Tessa Chu ◽  
Xiaopan Yao ◽  
...  
Keyword(s):  
Prospective Study ◽  
Index Score ◽  
Readmission Rates ◽  
Oncology Unit ◽  
A Prospective Study

scholarly journals The Practice of Medical Oncology in Morocco: The National Study of the Moroccan Group of Trialist in Medical Oncology (EVA-Onco)

ISRN Oncology ◽  
2013 ◽  
Vol 2013 ◽  
pp. 1-4 ◽  
Author(s):  
Saber Boutayeb ◽  
Amina Taleb ◽  
Rizlane Belbaraka ◽  
Nabil Ismaili ◽  
Narjiss Berrada ◽  
...  
Keyword(s):  
Missing Data ◽  
Prospective Study ◽  
Medical Oncology ◽  
National Study ◽  
National Strategy ◽  
Medical Oncologist ◽  
Cancer Centers ◽  
Medical Oncologists ◽  
A Prospective Study ◽  
The University

Objective. To determine the current shortfall of medical oncologists (MOs) and the projected supply. Background. Morocco, the medical oncology (MO) is a relatively new specialty. Medical oncology was recognized as a separate specialty in 1994 but the real taking-off was done only since the 2000s after the creation of the chair of medical oncology in the University of Rabat. The GRIOMM (Moroccan group of trialist in medical oncology) was created in 2011 and conducted its first study, EVA-onco, concerning the practice of medical oncology in Morocco in 2011. Design. EVA-onco is a prospective study concerning the practice of medical oncology in Morocco in 2011. Results. The entire public cancer centers completed the survey. There were no missing data. The number of medical oncologist per 100000/habitants in Morocco was 0.09. The average number of new patients seen per medical oncologist was 718 patients (ranging by state from 97 to 1875). The shortfall of MOs was estimated at 26 at least in 2011 according to the national recommendations. Conclusions. Since 2010, a national strategy to increase the capacity of MO workforce existed. The current shortfall of MO is expected to disappear in the future.

Impact of clinical pharmacists in an inpatient medical oncology service: A prospective study at a comprehensive cancer center in Jordan

2020 ◽  
pp. 107815522094327
Author(s):  
Nour Faqeer ◽  
Nour Mustafa ◽  
Noor Abd Al-jalil ◽  
Tasnim Qur’an
Keyword(s):  
Prospective Study ◽  
Medical Oncology ◽  
Cost Savings ◽  
Comprehensive Cancer Center ◽  
Cancer Center ◽  
Clinical Pharmacists ◽  
Oncology Service ◽  
A Prospective Study ◽  
The Impact

Introduction Clinical pharmacy is considered an integral discipline in the health care system for optimizing therapy and reducing drug-related problems. The objective of this study was to evaluate the impact of clinical pharmacists in optimizing management in a medical oncology service. Methods A prospective study was conducted at King Hussein Cancer Center between July 2019 and September 2019 of patients admitted to the medical oncology service. The impact of clinical pharmacists was measured by evaluating their interventions, defined as actions that were expected to result in a change in patient management. Data were collected daily by routine review of patients' profiles and by recording clinical pharmacists’ interventions. The data collected were baseline characteristics of patients, numbers and types of clinical pharmacists’ interventions, their significance, medications involved, and rate of acceptance of clinical pharmacists’ interventions by physicians. The significance of each intervention was assessed by two clinical pharmacists on a Hatoum scale. Physicians’ acceptance was assessed by whether the recommendations were implemented. Results During the study period, 748 patients were included, of whom 605 required a total of 1683 clinical interventions. The mean age was 56.3 years (±15.5 SD). Of the interventions, 39% resulted in initiation of a drug and 25% in drug discontinuations. The drug group most commonly associated with clinical pharmacists’ interventions was antibiotics (26.5%). Physicians accepted 98% of the clinical pharmacists’ interventions, and 92.4% of the interventions brought care to a more appropriate level and were considered significant. Conclusion Most patients in the medical oncology service required clinical pharmacists’ interventions, as demonstrated by the high number of significant clinical pharmacists’ interventions. Studies should be conducted to follow up these findings with respect to patient outcomes and cost savings.

Sign in / Sign up

Export Citation Format

Share Document